Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Merck and Parexel International have signed an agreement, under which Parexel will offer Merck BioVentures with strategic access to a range of regulatory strategy and clinical development planning capabilities for the development of certain classes of biosimilars across various therapeutic areas, including exclusivity for certain candidatesBioVentures.
Subscribe to our email newsletter
Merck and Parexel said that under the contract, a Merck BioVentures unit will be established within the Parexel organization.
Parexel chairman and CEO Josef von Rickenbach said they are committed to working with Merck BioVentures to assist in advancing its biosimilar portfolio in this rapidly developing market segment for the benefit of patients worldwide.
Merck BioVentures president Michael Kamarck said through this agreement, Merck BioVentures has secured strategic access to Parexel’s proven biosimilar clinical development experience.